Skip to content

aTyr Pharma ATYR Net margin

Net margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
15%+3.8pp
Merck & Co. logo
Merck & Co.MRK
13.6%-13.7pp
United Therapeutics logo
United TherapeuticsUTHR
40.6%+0.2pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-111.9%-51.5pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-529.2%-556pp
Zymeworks logo
ZymeworksZYME
-126.3%+5.0pp

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

Based on trailing twelve months.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's net margin?
aTyr Pharma (ATYR) reported net margin of -39,009.5% in Q4 2025.
How has aTyr Pharma's net margin changed year-over-year?
aTyr Pharma's net margin decreased by 43.2% year-over-year, from -27,243.8% to -39,009.5%.
What is the long-term trend for aTyr Pharma's net margin?
Over 3 years (2020 to 2025), aTyr Pharma's net margin has grown at a 531.1% compound annual growth rate (CAGR), from -155.2% to -39,009.5%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.